Allogene Therapeutics, Inc. (ALLO)
ALLO Stock Price Chart
Explore Allogene Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ALLO price movements and trends.
ALLO Company Profile
Discover essential business fundamentals and corporate details for Allogene Therapeutics, Inc. (ALLO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Oct 2018
Employees
226.00
Website
https://www.allogene.comCEO
David D. Chang
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
ALLO Financial Timeline
Browse a chronological timeline of Allogene Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.23.
Earnings released on 13 Aug 2025
EPS came in at -$0.23 surpassing the estimated -$0.28 by +17.86%.
Earnings released on 13 May 2025
EPS came in at -$0.28 matching the estimated -$0.28.
Earnings released on 13 Mar 2025
EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%, while revenue for the quarter reached -$22.00K , missing expectations by -283.33%.
Earnings released on 7 Nov 2024
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%.
Earnings released on 7 Aug 2024
EPS came in at -$0.32 surpassing the estimated -$0.35 by +8.57%.
Earnings released on 13 May 2024
EPS came in at -$0.38 matching the estimated -$0.38, while revenue for the quarter reached $22.00K , beating expectations by +120.00%.
Earnings released on 14 Mar 2024
EPS came in at -$0.43 surpassing the estimated -$0.47 by +8.51%, while revenue for the quarter reached $21.00K , beating expectations by +5.00%.
Earnings released on 2 Nov 2023
EPS came in at -$0.37 surpassing the estimated -$0.53 by +30.19%, while revenue for the quarter reached $43.00K , beating expectations by +115.00%.
Earnings released on 2 Aug 2023
EPS came in at -$0.53 surpassing the estimated -$0.59 by +10.17%, while revenue for the quarter reached $44.00K , beating expectations by +120.00%.
Earnings released on 3 May 2023
EPS came in at -$0.68 falling short of the estimated -$0.63 by -7.94%, while revenue for the quarter reached $52.00K , beating expectations by +420.00%.
Earnings released on 28 Feb 2023
EPS came in at -$0.66 surpassing the estimated -$0.71 by +7.04%, while revenue for the quarter reached $47.00K , missing expectations by -39.10%.
Earnings released on 2 Nov 2022
EPS came in at -$0.58 surpassing the estimated -$0.62 by +6.45%, while revenue for the quarter reached $49.00K , beating expectations by +583.69%.
Earnings released on 9 Aug 2022
EPS came in at -$0.52 surpassing the estimated -$0.61 by +14.75%, while revenue for the quarter reached $86.00K , beating expectations by +594.39%.
Earnings released on 4 May 2022
EPS came in at -$0.56 surpassing the estimated -$0.59 by +5.08%, while revenue for the quarter reached $61.00K , beating expectations by +632.03%.
Earnings released on 23 Feb 2022
EPS came in at -$0.54 surpassing the estimated -$0.61 by +11.48%, while revenue for the quarter reached $51.00K , missing expectations by -9.09%.
Earnings released on 4 Nov 2021
EPS came in at -$0.57 falling short of the estimated -$0.56 by -1.79%, while revenue for the quarter reached $49.00K , beating expectations by +390.00%.
Earnings released on 4 Aug 2021
EPS came in at -$0.53 surpassing the estimated -$0.55 by +3.64%, while revenue for the quarter reached $44.00K , missing expectations by -80.87%.
Earnings released on 5 May 2021
EPS came in at -$0.25 surpassing the estimated -$0.48 by +47.92%, while revenue for the quarter reached $38.35M , beating expectations by +198.64%.
Earnings released on 25 Feb 2021
EPS came in at -$0.53 surpassing the estimated -$0.56 by +5.36%.
Earnings released on 4 Nov 2020
EPS came in at -$0.52 surpassing the estimated -$0.55 by +5.45%.
ALLO Stock Performance
Access detailed ALLO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.